June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Preclinical safety profile of a preservative free gellan gum/ sodium hyaluronate artificial tear combination
Author Affiliations & Notes
  • Paloma Marquez
    Medical management, Laboratorios Sophia, Zapopan, Mexico
  • Leopoldo Martin Baiza-Duran
    Medical management, Laboratorios Sophia, Zapopan, Mexico
  • Yussett Contreras
    Medical management, Laboratorios Sophia, Zapopan, Mexico
  • Oscar Olvera Montaño
    Medical management, Laboratorios Sophia, Zapopan, Mexico
  • Juan D Quintana-Hau
    Pharmaceutical development, Laboratorios Sophia, Zapopan, Mexico
  • Juan Carlos Rivera
    Pharmaceutical development, Laboratorios Sophia, Zapopan, Mexico
  • Footnotes
    Commercial Relationships Paloma Marquez, Laboratorios Sophia S.A de C.V (E); Leopoldo Baiza-Duran, Laboratorios Sophia S.A de C.V (E); Yussett Contreras, Laboratorios Sophia S.A de C.V (E); Oscar Olvera Montaño, Laboratorios Sophia S.A de C.V (E); Juan Quintana-Hau, Laboratorios Sophia S.A de C.V (E); Juan Rivera, Laboratorios Sophia S.A de C.V (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4480. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paloma Marquez, Leopoldo Martin Baiza-Duran, Yussett Contreras, Oscar Olvera Montaño, Juan D Quintana-Hau, Juan Carlos Rivera; Preclinical safety profile of a preservative free gellan gum/ sodium hyaluronate artificial tear combination. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4480.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the clinical and histopathological safety of a gellan gum/sodium hyaluronate based new artificial tear, when applied to rabbit eyes.

Methods: Thirty healthy male New Zealand White rabbits (60 eyes) were included in this study. The preservative free gellan gum 0.35%/ sodium hyaluronate 0.5% ophthalmic solution was applied 4 times a day for 30 days in both eyes. Slit lamp examination (conjunctival hyperemia, chemosis and conjunctival discharge evaluation) and corneal staining were performed on days 2, 5, 10, 15, 20, 25 and 30 of the study. On day 31 rabbits were sacrificed and enucleated for hysthopathological assessment.

Results: Conjunctival hyperemia, graded minimal or mild, was encountered through all the evaluations, being statistically significant compared with baseline (p<0.05), reaching its highest peak on day 20, with 36.7% (n= 22). On day 2, conjunctival discharge was present in 8.3% (n=5), also reaching a statistically significant difference compared with baseline. No hystopathological changes were reported.

Conclusions: The security parameters evaluated in this study showed that the combination of gellan gum/sodium hyaluronate is clinically and histologically safe and non-toxic to the ocular surface. Further studies are warranted to assess the impact of this formulation on tear film stability and corneal protection.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×